# US 2017/0253922 A1 · Human identification using a panel of snps

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0253922 A1
- Document ID: US20170253922A1
- Status: Published application
- Kind: A1
- Application number: 15/466,797
- Filed: 2017-03-22
- Published: 2017-09-07
- Earliest claimed: 2012-07-14
- Assignees: Life Technologies Corporation
- Applicants: Life Technologies Corporation
- Inventors: Robert LAGACE
- Web page: https://patentgrep.com/patent/US20170253922A1

## CPC

- C12Q 1/6853: using modified primers or templates
- C12Q 1/6855: Ligating adaptors
- C12Q 1/6888: for detection or identification of organisms
- C12Q 2521/531: Glycosylase
- C12Q 2525/131: incorporating a restriction site
- C12Q 2537/143: Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention provides methods, compositions, kits, systems and apparatus that are useful for multiplex PCR of one or more nucleic acids which belong to a panel of single nucleotide polymorphisms (SNPs) useful to identify a human. In particular, various target-specific primers are provided that allow for the selective amplification of one or more target sequences in the panel. In some aspects, amplified target sequences obtained using the disclosed methods, kits, systems and apparatuses can be used in various downstream processes including nucleic acid sequencing and used to identify a human.

## Claims

### Claim 1

A method comprising:
a) amplifying a plurality of different target sequences within a sample comprising:
b) amplifying within a single amplification reaction mixture a plurality of different target sequences wherein the target sequences are a panel of at least fifty single nucleotide polymorphism (SNP) regions selected from Table A, wherein the amplifying includes contacting at least some portion of the sample with a plurality of target-specific primers and a polymerase under amplification conditions, thereby producing an amplified plurality of target sequences wherein at least two of the different amplified target sequences are less than 50% complementary to each other and wherein at least one of the plurality of amplified target sequences includes a cleavable group, wherein the cleavable group is uracil;
c) cleaving a cleavable group of at least one amplified target sequence of the amplified plurality of target sequences;
d) ligating at least one adapter to at least one amplified target sequence in a blunt-ended ligation reaction, thereby producing one or more adapter-ligated amplified target sequences, and
e) reamplifying at least one of the adapter-ligated amplified target sequences, wherein at least one target-specific primer is substantially complementary to at least a portion of a corresponding target sequence in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein one or more of the at least one adapter is not substantially complementary to at least one amplified target sequence.

### Claim 3 (depends on 1)

The method of claim 1, wherein the reamplifying includes contacting the at least one adapter-ligated amplified target sequence with one or more primers including a sequence that is complementary to at least one of the adapters or their complement, and a polymerase under amplification conditions, thereby producing at least one reamplified adapter-ligated amplified target sequence.

### Claim 4 (depends on 3)

The method of claim 3, wherein at least one of the one or more adapters or their complements is not substantially complementary to at least one amplified target sequence.

### Claim 5 (depends on 1)

The method of claim 1, wherein an adapter that is ligated to at least one of the amplified target sequences is susceptible to exonuclease digestion.

### Claim 6 (depends on 1)

The method of claim 1, wherein an adapter that is ligated to at least one of the amplified target sequences does not include a protecting group.

### Claim 7 (depends on 1)

The method of claim 1, wherein the ligating includes contacting at least one amplified target sequence having a 3′ end and a 5′end with a ligation reaction mixture including one or more adapters and a ligase under ligation conditions, wherein none of the adapters in the ligation reaction mixture includes, prior to the ligating, a target sequence.

### Claim 8 (depends on 7)

The method of claim 7, wherein the ligating includes contacting at least one amplified target sequence with a ligation reaction mixture including one or more adapters and a ligase under ligation conditions, wherein the ligation reaction mixture does not include one or more additional oligonucleotide adapters prior to ligating the one or more adapters to at least one amplified target sequence.

### Claim 9 (depends on 1)

The method of claim 1, wherein the amplified product is subject to an enzymatic manipulation step prior to the ligating, to produce a plurality of blunt-end amplified target sequences possessing a 5′ phosphate group.

### Claim 10 (depends on 1)

The method of claim 1, wherein each primer pair has at least one uracil nucleotide near the terminus of each forward and reverse primer.

### Claim 11 (depends on 1)

The method of claim 1, wherein the plurality of different target sequences are a panel of at least fifty SNPs selected from rs1004357, rs10092491, rs1019029, rs10500617, rs1058083, rs10768550, rs10773760, rs10776839, rs12480506, rs12997453, rs13134862, rs13182883, rs13218440, rs1358856, rs1410059, rs1478829, rs1490413, rs1498553, rs1523537, rs1554472, rs159606, rs1736442, rs1821380, rs1872575, rs2073383, rs214955, rs2175957, rs2255301, rs2269355, rs2270529, rs2272998, rs2291395, rs2292972, rs2342747, rs2567608, rs2811231, rs2833736, rs321198, rs338882, rs3744163, rs3780962, rs4288409, rs430046, rs4530059, rs4606077, rs464663, rs4789798, rs521861, rs560681, rs576261, rs590162, rs6444724, rs6591147, rs6811238, rs689512, rs6955448, rs7041158, rs7229946, rs740598, rs7520386, rs7704770, rs8070085, rs891700, rs901398, rs9546538, rs9606186, rs985492, rs9866013, rs987640, rs9951171, rs1005533, rs1024116, rs1028528, rs1029047, rs10495407, rs1355366, rs1357617, rs1382387, rs1413212, rs1454361, rs1463729, rs1493232, rs1886510, rs1979255, rs2040411, rs2056277, rs2107612, rs2111980, rs251934, rs354439, rs717302, rs719366, rs722098, rs727811, rs729172, rs733164, rs735155, rs737681, rs873196, rs876724, rs914165, rs917118, and rs964681.

### Claim 12 (depends on 11)

The method of claim 11, wherein the plurality of different target sequences are a panel of SNP's comprising rs1004357, rs10092491, rs1019029, rs10500617, rs1058083, rs10768550, rs10773760, rs10776839, rs12480506, rs12997453, rs13134862, rs13182883, rs13218440, rs1358856, rs1410059, rs1478829, rs1490413, rs1498553, rs1523537, rs1554472, rs159606, rs1736442, rs1821380, rs1872575, rs2073383, rs214955, rs2175957, rs2255301, rs2269355, rs2270529, rs2272998, rs2291395, rs2292972, rs2342747, rs2567608, rs2811231, rs2833736, rs321198, rs338882, rs3744163, rs3780962, rs4288409, rs430046, rs4530059, rs4606077, rs464663, rs4789798, rs521861, rs560681, rs576261, rs590162, rs6444724, rs6591147, rs6811238, rs689512, rs6955448, rs7041158, rs7229946, rs740598, rs7520386, rs7704770, rs8070085, rs891700, rs901398, rs9546538, rs9606186, rs985492, rs9866013, rs987640, rs9951171, rs1005533, rs1024116, rs1028528, rs1029047, rs10495407, rs1355366, rs1357617, rs1382387, rs1413212, rs1454361, rs1463729, rs1493232, rs1886510, rs1979255, rs2040411, rs2056277, rs2107612, rs2111980, rs251934, rs354439, rs717302, rs719366, rs722098, rs727811, rs729172, rs733164, rs735155, rs737681, rs873196, rs876724, rs914165, rs917118, and rs964681.

### Claim 13 (depends on 1)

The method of claim 1, wherein the plurality of different target sequences are a panel of all the SNP's of Table A.

### Claim 14 (depends on 1)

The method of claim 1, wherein the sample is genomic DNA, formalin-fixed paraffin-embedded (FFPE) DNA, or a nucleic acid molecule obtained from a forensic sample, a biopsy, a tumor, scrapings, swabs, blood, mucus, urine, plasma, semen, hair, laser capture micro-dissections, or surgical resections.

### Claim 15 (depends on 1)

The method of claim 1, wherein the sample is from a single individual, a collection of nucleic acid samples from genetically related members, multiple nucleic acid samples from genetically unrelated members, multiple nucleic acid samples from a single individual, a tumor sample and normal tissue sample from a single individual, genetic material from a single source that contains two distinct forms of genetic material such as maternal and fetal DNA obtained from a maternal subject, newborn nucleic acid sample, or contaminating bacteria DNA in a sample that contains plant or animal DNA.

### Claim 16 (depends on 1)

The method of claim 1, further comprising identifying a human based on the amplicons of the panel of SNP's amplified.
